LONG-TERM STANDARDIZED OUTCOMES WITH A NEW EXTENDED DEPTH OF FOCUS INTRAOCULAR LENS DESIGN IN REAL WORLD CLINICAL PRACTICE

This study aims to evaluate the safety, efficacy, and patient-reported outcomes of the ELON intraocular lens over a 12-month follow-up period in real-world clinical settings.

Qvision, Ophthalmology Department, VITHAS Almería, Spain.

Data were retrospectively collected from our historical database for 21 subjects, with 11 completing the 12-month follow-up. This cohort included patients from real-world clinical practice: one underwent laser refractive surgery, four had a history of Glaucoma, one had a postoperative retinal detachment treated during the follow-up, and remaining patients without comorbidities. Visual acuities (VAs) were measured at far (4m), intermediate (66cm), and near (40cm) distances, both corrected and uncorrected. Patient-reported outcomes were evaluated at 12 months using the Patient Reported Spectacle Independence (SI) Questionnaire (PRSIQ), alongside five individual questions assessing the cumulative percentage of patients satisfied with postoperative uncorrected vision, experiencing bothersome photic phenomena, and willing to undergo the same procedure again.

The 3-month follow-up demonstrated a mean monocular distance corrected VAs of 0.03, 0.16, and 0.33 logMAR for far, intermediate, and near distances, respectively. The 12-month follow-up revealed binocular uncorrected visual acuities of 0.04, 0.16, and 0.17 logMAR, respectively. Far distance SI was achieved in 100% of patients, 83% at intermediate, and 13% at near. There was a notable improvement in patient-reported outcomes from 3 to 12 months, particularly in satisfaction with vision without spectacles at near distance, with 3 patients dissatisfied at 3-month and neutral or satisfied at 12-month as the remaining sample. Among the 12 patients who completed the 12-month follow-up, all were willing to be operated on again with the same IOL, including the patient who had postoperative retinal detachment treated during the follow-up. Positive dysphotopsia also improved from 3- to 12-months with 54% to 100% of patients none or slightly bothered, respectively.

Patients implanted with the ELON lens exhibited enhanced patient-reported outcomes from 3 to 12 months. Despite varied ocular conditions, all participants expressed willingness to undergo the procedure again. Future studies with higher sample sizes should determine for which comorbidities ELON can be a suitable option that covers patient expectations.